Conduit Pharmaceuticals Inc. has announced the postponement of its 2024 Annual Meeting of Stockholders, which was originally scheduled for October 2, 2024. The new date for the Annual Meeting is set for December 18, 2024, with the record date being October 25, 2024. This decision was made by the Board of Directors, who deemed the delay to be in the best interests of the stockholders. The company, which did not hold an annual meeting in 2023, has also provided a deadline for the submission of qualified stockholder proposals or director nominations. According to the Securities Exchange Act of 1934 and the company's bylaws, the cut-off for proposals or nominations to be included in the proxy statement is September 16, 2024. All submissions must adhere to the requirements of the SEC's rules and regulations, including Rule 14a-8. The report was signed by Dr. David Tapolczay, CEO of Conduit Pharmaceuticals.

Conduit Pharmaceuticals Inc. has announced the postponement of its 2024 Annual Meeting of Stockholders, which was originally scheduled for October 2, 2024. The new date for the Annual Meeting is set for December 18, 2024, with the record date being October 25, 2024. This decision was made by the Board of Directors, who deemed the delay to be in the best interests of the stockholders. The company, which did not hold an annual meeting in 2023, has also provided a deadline for the submission of qualified stockholder proposals or director nominations. According to the Securities Exchange Act of 1934 and the company's bylaws, the cut-off for proposals or nominations to be included in the proxy statement is September 16, 2024. All submissions must adhere to the requirements of the SEC's rules and regulations, including Rule 14a-8. The report was signed by Dr. David Tapolczay, CEO of Conduit Pharmaceuticals.